share_log

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

诺和诺德公司在治疗2型糖尿病方面又一次获得每周一次的胰岛素Icodec胜利
Benzinga Real-time News ·  2022/10/03 13:54
  • Novo Nordisk A/S (NYSE:NVO) has completed posting topline results across its six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in people with diabetes.
  • In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study.
  • Novo's icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily control. The study comprised 1,085 insulin-naive people with type 2 diabetes. Patients on icodec also used an app to guide their dosing.
  • The news adds to ONWARDS trial readouts dating back to April.
  • In July, the company announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec.
  • Earlier this month, Novo picked up worldwide marketing rights to Zealand Pharma A/S's (NASDAQ:ZEAL) diabetes treatment Zegalogue and inked a $1.1 billion buyout of Forma Therapeutics Holdings Inc (NASDAQ:FMTX) for its sickle cell drug.
  • Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the U.S., the EU, and China in 1H of 2023.
  • Price Action: NVO shares are up 2.26% at $101.88 on the last check Monday.
  • 诺和诺德A/S(纽约证券交易所股票代码：NVO)已经完成了糖尿病患者每周一次的胰岛素icodec后续计划的6个3a期临床试验的TOPLINE结果。
  • 在接下来的5项研究中，发现每周一次的胰岛素icodec在降低HbA1c方面不逊于每天一次的基础胰岛素。至此，为期52周的开放标签试验在研究结束时达到了主要终点。
  • Novo的icodec导致HbA1c的降幅为-1.68%，而每日一次的控制组为-1.31%。这项研究包括1,085名未服用胰岛素的2型糖尿病患者。服用icodec的患者还使用了一款应用程序来指导他们的剂量。
  • 这一消息增加了自4月份以来的试验读数。
  • 今年7月，该公司宣布了使用每周一次的胰岛素icodec进行的3期和4期3a试验的主要结果。
  • 本月早些时候，Novo获得了全球营销权新西兰医药A/S的糖尿病治疗药物Zegalogue并签署了11亿美元的收购协议Forma治疗控股公司(纳斯达克代码：FMTX)为其镰状细胞药物。
  • 诺和诺德预计将于2023年上半年在美国、欧盟和中国申请每周一次的胰岛素icodec的监管批准。
  • 价格行动：周一收盘时，NVO股价上涨2.26%，至101.88美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发